Findings and insights related to nursing and virtual reality, AI and infusions were just some of the topics covered at the ...

In addition to the presentations, Viral Kansara, PhD, Vice President, Preclinical Development moderated an ARVO session entitled "Retina/RPE: New drugs, mechanisms of action, and toxicity” and Dr.

Premeds can get an edge by being published several ways, from hypothesis-based research papers to conference abstracts.

In January 2025, Sagimet delivered an oral presentation at the 9 th Annual MASH-TAG Conference highlighting the ...

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.

Getting published looks good on your medical school application and indicates that you can dig deep into research and follow through. It can also boost your residency and fellowship applications ...

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a ...

Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have ...

NEW YORK, May 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX ) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...